Incyte (INCY) Financial Analysis & Valuation | Quarter Chart
Incyte (INCY)
INCYPrice: $92.03
Fair Value: 🔒
🔒score
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growt... more
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commerci... more
Description
Shares
| Market Cap | $18.32B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William J. Meury |
| IPO Date | 1993-11-04 | CAGR | 0.36% |
| Employees | 2,617 | Website | www.incyte.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.11% | Total Yield | 0.11% |
INCY chart loading...
Fundamentals
Technicals
| Enterprise Value | $15.37B | P/E Ratio | 14.56 |
| Forward P/E | 10.72 | PEG Ratio | 0.16 |
| P/S Ratio | 4.18 | P/B Ratio | 4.18 |
| P/CF Ratio | 17.16 | P/FCF Ratio | 17.86 |
| EPS | $6.32 | EPS Growth 1Y | 2274.07% |
| EPS Growth 3Y | 321.71% | EPS Growth 5Y | -558.02% |
| Revenue Growth 1Y | 21.22% | Gross Margin | 0.92% |
| Operating Margin | 0.29% | Profit Margin | 0.25% |
| ROE | 0.29% | ROA | 0.18% |
| ROCE | 0.28% | Current Ratio | 3.33 |
| Quick Ratio | 3.04 | Cash Ratio | 2.04 |
| Debt/Equity | 0.01 | Interest Coverage | 1198.46 |
| Altman Z Score | 8.38 | Piotroski Score | 6 |